Last Updated: 2 June 2026
Ilant Health has raised $15 million in Series A funding to expand its obesity and cardiometabolic care program, which works directly with employers and health plans rather than individual patients. The company was founded by Elina Onitskansky, who previously held roles at McKinsey and Molina Healthcare, and is built around a value-based care model — one in which the company is paid based on the health outcomes it produces, not simply for delivering services. Total funding now stands at over $22 million.
The financial pressure behind this raise is easy to understand. GLP-1 medications, a class of drugs used for weight loss and diabetes management — think Ozempic and Wegovy — saw total employer spending rise by around 50 percent in 2025, according to SHRM, citing Aon data. They now account for roughly 20 percent of all prescription drug costs. Most employers are caught between two bad options: cover these drugs and absorb rapidly rising pharmacy bills, or restrict access and risk worsening chronic disease among their workforce. According to Peterson-KFF, only 19 percent of firms with 200 or more workers currently cover GLP-1s for weight loss, though that figure climbs to 43 percent among the largest employers, those with 5,000 or more workers. Many are already pulling back.
The Series A was led by Cornucopian Capital, a Montclair, New Jersey-based venture firm that backs companies at the intersection of science and consumer health. Other participants include naturalX, Peakbridge, Semcap AI, Evidenced, and Operator Partners, joined by returning investors Celtic, LifeX, and AlphaLab.
Obesity is connected to more than 60 chronic conditions, including type 2 diabetes, heart disease, and depression. Most health systems have dealt with it through separate, disconnected programs: a behavioral counseling service here, a medication there, with no coordinated approach tying outcomes together. Ilant argues that this structure is a big part of why results are poor and costs stay high.
The company builds an individual treatment plan for each member using clinical, behavioral, and personal data. That plan might include behavioral therapy, medication — GLP-1 or otherwise — or surgery, depending on what the evidence supports for that person. Nutrition, physical activity, and stress management are part of the picture too. Critically, the treatment plan is not static: it gets adjusted over time based on how each individual actually responds.
"We believe the next generation of category-defining companies will be those that deliver outcomes as a service, not just tools or access. Ilant is applying that model to one of the most important and costly areas in healthcare. The company understands that the future of obesity and cardiometabolic care will not be defined by access to a single class of drugs, but by the ability to deliver the right care to the right patient at the right time. Their model aligns clinical rigor with economic value in a way that we believe will define this category over the next decade."
Aryeh Ganz, Founder and Managing Partner, Cornucopian Capital
Ilant already has employer clients in place. The SEIU 775 Benefits Group, which provides benefits to healthcare workers across the Pacific Northwest, is one of them. The company has also negotiated direct contracting arrangements with both Eli Lilly and Novo Nordisk, the two dominant manufacturers of GLP-1 medications. In November 2025, Ilant formalized its arrangement with Lilly through the company's Employer Connect program.
These contracts let Ilant offer employers pre-negotiated, transparent pricing on obesity medications rather than the opaque pricing structures that often come through standard pharmacy benefit channels. That matters because the market is moving fast. Eli Lilly's combined GLP-1 sales reached $36.5 billion in 2025, as reported by the Financial Times and other major outlets. Employers who lack pricing visibility in this category are flying blind on one of their biggest and fastest-growing cost lines.
"Employers and health plans are facing a real dilemma right now — they are faced with either expanding access and watching pharmaceutical costs rise dramatically, or restricting access and risking rising chronic disease and cost. That's not a sustainable model. If we don't change how care is delivered, we're just paying more for the same broken system, and we risk a crisis where both chronic disease and costs are spiraling out of control. Ilant's model focuses on delivering real value with manageable treatment costs and clinically meaningful care that actually bends the cost curve."
Elina Onitskansky, Founder and CEO, Ilant Health
Ilant Health functions as a managed care service. Employers and health plans contract with the company, which then takes responsibility for the full care journey of covered members: assessment, diagnosis, treatment, medication management, and ongoing behavioral support. The idea is that a member with obesity should have one place to go, not a patchwork of referrals.
Early data from current members shows an average weight loss of 15 percent over one year, compared to 5.8 percent in typical real-world settings. Members also report gaining an average of two additional mentally healthy days per month. Biometric markers such as blood pressure, cholesterol, and blood sugar levels show measurable improvement as well. The company is careful to frame these as clinical outcomes rather than cosmetic ones, which speaks to how it positions its value to payers.
The leadership team includes Chief Medical Officer Kara Mayes, an obesity medicine specialist, along with Chief Operating Officer Jessica Muse, Chief Product Officer Mark Rickabaugh, and Data Scientist Steven Marchette. Susannah Fox, former Chief Technology Officer of the U.S. Department of Health and Human Services, sits on the advisory board.
Cornucopian Capital led the raise. The firm describes its thesis around what it calls Medicine 3.0, a focus on companies that use data and science to shift healthcare away from treating established disease and toward preventing it. Prior investors Celtic, LifeX, and AlphaLab rejoined the round. New participants include naturalX, Peakbridge, Semcap AI, Evidenced, and Operator Partners. The combination of healthcare-oriented and AI-focused investors reflects where Ilant sits: between clinical care delivery and data-driven personalization.
